Mostrar registro simples

dc.contributor.authorAndreis, Tiago Fingerpt_BR
dc.contributor.authorCorrêa, Bruno da Silveirapt_BR
dc.contributor.authorVianna, Fernanda Sales Luizpt_BR
dc.contributor.authorParis, Fernanda dept_BR
dc.contributor.authorSiebert, Marinapt_BR
dc.contributor.authorLeistner-Segal, Sandrapt_BR
dc.contributor.authorHahn, Eriza Cristinapt_BR
dc.contributor.authorUlbrich, Jane Mariapt_BR
dc.contributor.authorOliveira, Francine Hehn dept_BR
dc.contributor.authorRivero, Luis Fernando da Rosapt_BR
dc.contributor.authorLorandi, Viníciuspt_BR
dc.contributor.authorProlla, Patrícia Ashtonpt_BR
dc.contributor.authorMacedo, Gabriel de Souzapt_BR
dc.date.accessioned2021-11-25T04:38:31Zpt_BR
dc.date.issued2019pt_BR
dc.identifier.issn2378-9506pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/232208pt_BR
dc.description.abstractPURPOSE Adenocarcinoma is the most common histologic subtype of non–small-cell lung cancer, representing 40% of all diagnoses. Several biomarkers are currently used to determine patient eligibility for targeted treatments, including analysis of molecular alterations in EGFR and ALK, as well as programmed death-ligand 1 (PD-L1) protein expression. Epidemiologic data reporting the frequency of these biomarkers in Brazilian patients with lung adenocarcinoma (LUAD) are limited, and existing studies predominantly included patients from the southeast region of the country. MATERIALS AND METHODS The goal of this study was to investigate the frequency of somatic mutations in the EGFR, KRAS, NRAS, and BRAF genes, ALK, and PD-L1 expression in a series of Brazilian patients diagnosed with LUAD predominantly recruited from centers in southern Brazil. Molecular analysis of the EGFR, KRAS, NRAS, and BRAF genes was performed by next-generation sequencing using DNA extracted from tumor tissue. Immunohistochemistry was used to detect ALK and PD-L1 expression. RESULTS Analysis of 619 tumors identified KRAS mutations in 189 (30.2%), EGFR mutations in 120 (19.16%), and BRAF mutations in 19 (3%). Immunohistochemistry demonstrated ALK and PD-L1 expression in 4% and 35.1% of patients, respectively. CONCLUSION To our knowledge, this is the first study investigating the molecular epidemiology of patients with LUAD from southern Brazil and the largest assessing the frequency of multiple predictive biomarkers for this tumor in the country. The study also reveals a distinct mutation profile compared with data originating from other regions of Brazil.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofJournal of global oncology. Alexandria. Vol. 5 (2019), 9 p.pt_BR
dc.rightsOpen Accessen
dc.subjectPrognósticopt_BR
dc.subjectBiomarcadorespt_BR
dc.subjectAdenocarcinoma de pulmãopt_BR
dc.subjectBrasilpt_BR
dc.titleAnalysis of predictive biomarkers in patients with lung adenocarcinoma from Southern Brazil reveals a distinct profile from other regions of the countrypt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001133096pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples